INVO

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic centers for its clinical trial evaluating the safety and efficacy of NY-303, its GPC3-targeting NK Engager bispecific antibody, as a monotherapy for the treatment of hepatocellular carcinoma in patients n

RW - NAYA Biosciences, Inc. (0001417926) (Filer)

SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (NASDAQ:INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases through the merger of INVO Biosciences and NAYA Biosciences, today confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the new symbol "NAYA" at the market open on Tuesday, October 22, 2024. The CUSIP number for the Company's common stock will remain unchanged. The name and symbol change follows the Company's recent announcement on October 14th regarding the completion of its merger with NAYA Biosciences. The newly combine

8-K - INVO Bioscience, Inc. (0001417926) (Filer)

SARASOTA, Fla. and MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience ("INVO") (NASDAQ:INVO) today announced it has closed its merger with NAYA Biosciences, a company dedicated to increasing patient access to breakthrough treatments in oncology and autoimmune diseases. The combined company expects to change its name to NAYA Biosciences and trade on the NASDAQ under the "NAYA" ticker. The combined company will continue to operate the revenue-generating fertility business as well as expand its focus to the development of first-in-class clinical-stage assets in oncology and autoimmune diseases. The combined company will be led by INVO Chief Executive Officer Steve Shum, INVO Chief Fina

8-K - INVO Bioscience, Inc. (0001417926) (Filer)

8-K - INVO Bioscience, Inc. (0001417926) (Filer)

8-K - INVO Bioscience, Inc. (0001417926) (Filer)

8-K - INVO Bioscience, Inc. (0001417926) (Filer)

10-Q - INVO Bioscience, Inc. (0001417926) (Filer)

SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the second quarter 2024 for the period ended June 30, 2024 and provided a business update. Q2 2024 Financial Highlights (all metrics compared to Q2 2023 unless otherwise noted) Revenue was $1,836,597, an increase of 481% compared to $315,902. Revenue increased 17% sequentially compared to Q1 2024.

8-K - INVO Bioscience, Inc. (0001417926) (Filer)

-SEC Filing 

8-K - INVO Bioscience, Inc. (0001417926) (Filer)

S-3 - INVO Bioscience, Inc. (0001417926) (Filer)

8-K - INVO Bioscience, Inc. (0001417926) (Filer)

INVO Bioscience (NASDAQ:INVO) reported quarterly losses of $(0.42) per share. The company reported $1.58 million in sales this quarter. This is a 352.84 percent increase over sales of $348.02 thousand the same period last year.

Gainers SINTX Techs (NASDAQ:SINT) shares increased by 22.2% to $0.16 during Wednesday's after-market session. The company's market cap stands at $19.1 million. As per the news, the Q1 earnings report came out 2 days ago. Petros Pharma (NASDAQ:PTPI) shares rose 12.85% to $0.58. The market value of their outstanding shares is at $4.0 million. Bluejay Diagnostics (NASDAQ:BJDX) shares increased by 10.22% to $0.58. The market value of their outstanding shares is at $1.5 million. INVO Bioscience (NASDAQ:INVO) stock rose 7.47% to $1.15. The market value of their outstanding shares is at $4.3 million. Scorpius Holdings (AMEX:SCPX) shares moved upwards by 7.2% to $0.08. The market value of their

INVO Bioscience's (NYSE:INVO) short percent of float has risen 39.13% since its last report. The company recently reported that it has 17 thousand shares sold short, which is 0.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest

SARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the first quarter of 2024 and provided a business update. Q1 2024 Financial Highlights (all metrics compared to Q1 2023 unless otherwise noted) Revenue was $1,576,286, an increase of 353% compared to $348,025.Clinic revenue increased 417% to $1,537,199, compared to $297,381. All reported

10-Q - INVO Bioscience, Inc. (0001417926) (Filer)

Shares of Alibaba Group Holding Limited (NYSE:BABA) fell sharply during Tuesday's session following mixed first-quarter financial results. The e-commerce giant reported fiscal fourth-quarter 2023 revenue growth of 7% year-on-year to $30.73 billion, beating the analyst consensus estimate of $30.40 billion. Adjusted earnings per ADS of $1.40 missed the analyst consensus estimate of $1.41, according to data from Benzinga Pro. Alibaba Group shares tumbled 6.8% to $78.86 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Cheetah Net Supply Chain Service Inc. (NASDAQ:CTNT) shares jumped 352.4% to $5.34 as the company reported pricing of $8.19 million

Shares of Alcon Inc. (NYSE:ALC) rose sharply in today's pre-market trading following better-than-expected first-quarter earnings. Alcon posted adjusted earnings of 78 cents per share, beating market expectations of 63 cents per share. The company's quarterly sales came in at $2.444 billion versus estimates of $2.462 billion, according to data from Benzinga Pro. Alcon shares jumped 10.8% to $89.40 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers GameStop Corp. (NYSE:GME) gained 40.2% to $42.70 in pre-market trading after jumping over 74% on Monday. Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) gained 39.2% to $0.08

8-K - INVO Bioscience, Inc. (0001417926) (Filer)